Risk Group and Death From Prostate Cancer
Authors:
Open Access
- 1 June 2015
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 1 (3) , 334-340
Abstract
Treatment recommendations for men with localized prostate cancer (PC) are based on risk stratification.1 Men with low-risk PC who have a life expectancy of at least 10 years may be offered radical prostatectomy (RP), external-beam radiotherapy (EBRT), brachytherapy, or active surveillance (AS) as an initial treatment. Active surveillance involves monitoring the course of PC with the expectation to initiate curative treatment if the cancer progresses.1,2 Follow-up of AS consists of annual transrectal ultrasonographically guided needle biopsies of at least 12 cores, semiannual prostate-specific antigen (PSA) measurements, and annual digital rectal examinations (DREs). Progression on surveillance can include any of the following: Gleason grade 4 or 5 PC found on repeat biopsy; PC found in a greater number biopsy cores or occupying a greater amount of the prostate biopsy cores; or a new nodule felt on DRE. In earlier experience with AS, PSA kinetics were used as a marker of disease progression; however, the clinical utility of PSA measurement for predicting progression has since been questioned3: a rapid rise in PSA alone is no longer considered a reason to initiate curative treatment. Given the data from the Prostate Cancer Intervention vs Observation Trial (PIVOT)4 suggesting a lack of benefit in men with low-risk PC when managed with RP vs watchful waiting, AS has become the preferred option for these men. While men in the PIVOT study were considered less healthy than men in the Surveillance, Epidemiology and End Results (SEER)–Medicare population,5 the results suggested that men with low-risk PC might not be at an increased risk of death from PC during the first decade after diagnosis if actively monitored.6Keywords
This publication has 1 reference indexed in Scilit: